Лечение инфильтративной офтальмопатии

Инфильтративная офтальмопатия – наиболее частое экстратиреоидное проявление аутоиммунных заболеваний щитовидной железы. В 3–5% случаев она имеет тяжелое течение и требует назначения специальной терапии. Существование большого количества способов лечения офтальмопатии и появление новых свидетельствуют об отсутствии достаточно эффективного метода ее лечения. В настоящем обзоре предпринята попытка систематизировать имеющиеся данные. Также в обзоре представлены рекомендации консенсуса European Group on Graves' Orbitopathy (EUGOGO) по лечению офтальмопатии.

инфильтративная офтальмопатия, эндокринная офтальмопатия, лечение

1. Бровкина А.Ф. Эндокринная офтальмопатия. М.: Гоэтар Медиа, 2004.

2. Залевская А.Г., Благосклонная Я.В. Случай тяжелой офтальмопатии при эутиреозе // Пробл. эндокринол. 1985. №6. С. 40–41.

3. Balazs C., Kiss E., Vamos A., Molnar I, Farid N.R. 1998 Beneficial effect of pentoxyfilline on thyroid-associated ophthalmopathy // J. Clin. Endocrinol. Metab. V. 82. P. 1999–2002.

4. Bartalena L., Marcocci C., Pinchera A. Cytokine antagonists: new ideas for the management of Graves` ophthalmopathy // J. Clin. Endocrinol. Metab. 1996. V. 81. P. 446–448.

5. Bartalena L., Marcocci C., Tanda M.L. et al. Relation between therapy for hyperthyroidism and the course of Graves` ophtalmopathy // N. Engl. J. Med. 1998. V. 338. P. 73–78.

6. Bartalena L., Marcocci C., Manetti L., Tanda M.L. et al. Orbital radiotherapy for Graves` ophtalmopathy // Thyroid. 1998. V. 8. P. 439–441.

7. Bartalena L., Pinchera A., Marcocci C. Management of Graves` ophtalmopathy: reality and perspectives // Endocr. Rev. 2000. V. 21. P. 168–199.

8. Bartalena L., Marcocci C., Pinchera A. Graves` ophtalmopathy: a preventable disease. 2002. V. 146. P. 457–461.

9. Bartalena L. Glucocorticoids for Graves` ophtalmopathy: how and when // J. Clin. Endocrinol. Metab. 2005. V. 90. P. 5497–5499.

10. Bartalena L., Baldeschi L., Dickinson A.J. et al. Consensus statement of the European Group on Graves` orbitopathy (EUGOGO) on management of Graves` orbitopathy // Thyroid. 2008. V. 18. V. 3. P. 333–345.

11. Bartley G.B., Fatourechi V. et al. Long-term followup of Graves' ophthalmopathy in an incidence cohort // Ophthalmology. 1996. V. 103. P. 958–962.

12. Chang T.C., Kao S. C.S., Huang K.M. Octreotide and Graves` ophtalmopathy and pretibal myxoedema // Br. Med. 1992. V. 304. P. 580.

13. Dandona P. Methylprednisolone and Graves` ophtalmopathy // Br. Med. J. 1989. V. 298. P. 830.

14. Guy J., Fagien S., Donovan J. P., Rubin M. L. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy // Ophthalmology. 1989. V. 96. P. 1048–1052.

15. Hiromatsu Y., Kojima K., Ishisaka N. et al. Role of magnetic resonance imaging in thyroid-associated ophtalmopathy: its predictive value for therapeutic outcime of immunosuppressive therapy // Thyroid. 1992. V. 2. P. 299–305.

16. Hiromatsu Y., Tanaka K., Sato M. et al. Intravenous methylprednisolone pulse therapy of Graves` ophthalmopathy // Endocr. J. 1993. V. 40. P. 63–72.

17. Jarhult J., Rudberg C., Larsson E., Selvander H. et al. Graves` disease with moderate-severe endocrine ophthalmopathy – long term results of a prospective, randomozed study of total or subtotal thyroid resection // Thyroid. 2005. V. 15. P. 1157–1164.

18. Kauppinen Makelin R., Karmi A., Leinonen E. et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroidassociated ophthalmopathy // Acta Ophtalmol. Scand. 2002. V. 80. P. 316–321.

19. Kahaly G., Schrezenmeir J., Krauze U. et al. Ciclosporin and prednisone vs. Prednisone in treatment of Graves` ophthalmopathy: a controlled, randomized and prospective study. // Eur. J. Clin. Invest. 1986. V. 16. P. 415–422.

20. Kahaly G., Diaz M., Just M. et al. Role of ostreoscan and correlation with MR imaging in Graves` ophtalmopathy // Thyroid. 1995. V. 5. P. 107–111.

21. Kahaly G.J., Rosler H. P., Pitz S., Hommel G. Low-versus high-dose radiotherapy for Graves` ophtalmopathy: a randomized, single dlind trial // J. Clin Endocrinol. Metab. 2000. V. 85. P. 102–108.

22. Kahaly G. J., Pitz S., Hommel G., Dittmar M. Randomized, singleblind trial of intravenous versus oral steroid monotherapy in Graves` ophtalmopathy // J. Endocrinol. Metab. 2005. V. 90. P. 5234–5240.

23. Kendall Taylor P., Crombie A.L., Stephenson A.M. et al. Intravenous methylprednisolone in the treatment of Graves` ophtalmopathy // Br. Med. J. 1988. V. 297. P. 1574–1578.

24. Krassas G. E., Dumas A., Pontikides N., Kaltsas T. Somatostatin receptor scintigraphy andoctreotide treatment in patients with thyroid eye disease // Clin. Endocrinol. 1995. V. 42. P. 571–580.

25. Krassas G.E., Kaltsas T., Dumas A., Pontikides N., Tolis G. Lanreotide in the treatment of patients with thyroid eye disease // Eur. J. Endocrinol. 1997. V. 136. P. 416–422.

26. Krassas G. E., Wiersinga W.M. Modern conceptions of diagnostic and management of TAO // Thyroid Int. 2005. V. 4. P. 1–20.

27. Le Moli R., Baldeschi L., Seed P. et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves` ophtalmopathy // Thyroid. 2007. V. 12. P. 357–362.

28. Macchia P. E., Bagattini M., Lupoli G. et al. High-dose intravenous corticosteroid therapy for Graves` ophtalmopathy // J. Endocrinol. Invest. 2001. V. 24. P. 152–158.

29. Marcocci C., Bartalena L. et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves'ophthalmopathy: a comparative study // Clin. Endocrinol. 1987. V. 27. P. 33–42.

30. Marino M., Morabito E., Brunetto M.R. et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves` ophtalmopathy // Thyroid. 2000. V. 14. P. 403–406.

31. Marquez S.D., Lum B.L., McDougall I.R. et al. Long-term results of irradiation for patients with Graves` ophtalmopathy // Int. J. Rad. Oncol. Biol. Phys. 2001. V. 51. P. 766–774.

32. Menconi F., Marino M., Pinchera A., Rocchi L. et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves` ophtalmopathy treated with intravenous glucocorticoids // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 1653–1658.

33. Mourits M. P., Prummel M. F., Wiersina W. M., Koorneef L. Clinical activity score as a guide in the management of patients with Graves` ophtalmopathy // Clin. Endocrinol. 1997. V. 47. P. 9–14.

34. Nabipour I., Burger A., Moharreri M. Avicenna, the First to Discribe Thyroid-Related Orbitopathy // Thyroid. 2009. V. 19. N1. P. 7–8.

35. Nagayama Y., Izumi M., Kiriyama T. et al. Treatment of Graves` ophtalmopathy with high-dose intravennous methylprednisolone pulse therapy // Acta. Endocrinol. 1987. V. 116. P. 513–518.

36. Perros P., David R. et al. Azathioprine in the treatment of thyroidassociated ophthalmopathy // Acta. Endocrinol. 1990. V. 122 (1). P. 8–12.

37. Pinchera A., Bartalena L., Chiovato L., Marcocci C. Radiotherapy of Graves`ophthalmopathy. New York: Raven Press, 1984. P. 301–316.

38. Prummel M.F., Wiersinga W.M. Immunomodulatory treatment of Graves` ophtalmopathy // Thyroid. 1998. V. 8. P. 543–546.

39. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves` disease // JAMA. 1993. V. 269. P. 479–482.

40. Prummel M.F., Mourits M.P., Berghout A., Krenning E.P. et al. Prednisone and cyclosporine in the treatment of severe Graves` ophtalmopathy // N. Engl. J. Med. 1989. V. 321. P. 1353–1359.

41. Prummel M.F., Wiersinga W.M., Mourits M.P. et al. Amelioration of eye changes of Graves` ophtalmopathy by achieving euthyroidism // Acta. Endocrinol. 1989. V. 121 (Suppl. 2). P. 185–189.

42. Prummel M.F., Wiersinga W.M., Mourits M.P. et al. Effect of abnormal thyroid function on the severity of Graves` ophtalmopathy // Arch. Intern. Med. 1990. V. 150. P. 1098–1101.

43. Prummel M.F., Mourits M.P., Blank L. et al. Randomised doubleblind trial of prednisone versus radiotherapy in Graves` ophtalmopathy // Lancet. 1993. V. 342. P. 949–954.

44. Raza A. Anti-TNF theraputies in rheumatoid arthritis, Crohn`s disease, sepsis and myelodysplatic syndromes // Microsc. Res. Tech. 2000. V. 50. P. 229–235.

45. Salvi M., Vannucchi G. et al. Rituximab in the treatment of thyroid eye disease: science fiction? // Orbit. 2009. V. 28. P. 251-255.

46. Stamal F. G., Maciel R.M. et al. Colchicine in the treatment oft he inflammatory phase of Graves' ophthalmopathy: a prospective and randomized trial with prednisolone // Acta. Bras. Oftalmol. 2006. V. 69. P. 811–816.

47. Wakelkamp I.M., Tan. H., Saeed P. et al. Orbital irradiation for Graves` ophtalmopathy: is it safe? A long-term follow-up study // Ophthalmology. 2004. V. 111. P. 1557–1562.

48. Wall J.R., Strakosch C.R. et al. Thyroid binding antibodies and other immunological abnormalities in patien with Graves's ophthalmopathy: effect of cyclophosphamide // Clin. Endocrinol. 1979. V. 10 (1). P. 79–91.

49. Weetman A.P., Ludagte M., Mills P.V. et al. Cyclosporine improves Graves` ophtalmopathy. Lancet. 1983. V. 3. P. 486–489.

50. Wiersinga W.M., Bartalena L. Epidemiology and prevention of Graves` ophtalmopathy // Thyroid. 2002. V. 12. P. 855–860.